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ABSTRACT 
Benign prostatic hyperplasia (BPH) is the enlargement of the prostate, a walnut-sized 
gland located just below the bladder. Currently, two main treatment options are available 
for BPH patients: 5-alpha reductase inhibitors (finasteride) and alpha-1-adrenergic 
receptor antagonists. However, these drugs can produce undesirable side effects. In this 
study, the levels of antioxidant (superoxide dismutase (SOD), catalase (CAT) and 
reduced glutathione (GSH)), prostate specific antigen (PSA), relative prostate weight and 
phytochemicals were investigated in Tetracarpidium conophorum leaf extract on the 
development of BPH in male Wistar rat.  Thirty (30) animals were randomly divided into 
six groups of five animals each. All treatments were administered to animals concurrently 
for four (4) weeks. Group A (normal control) received olive oil subcutaneously and other 
groups (B, C, D, E and F) received subcutaneous injection of testosterone propionate. 
Tetracarpidium conophorum (100, 200 and 400 mg/kg body weight) was administered by 
oral gavage daily to Groups C, D and E respectively while Group F received finasteride. 
From the phytochemical screening result obtained, saponins, phenols, tannin, flavonoid, 
steroid, glycoside, terpenoids and alkaloids were present. Animals in group E showed 
significant decrease (p<0.05) in relative prostate weight (10×10
-4
±29×10
-5
g) and serum 
PSA level (91.83±5.78pg/ml) when compared to relative prostate weight (17×10
-
4
±84×10
-6
g) and serum PSA level (174.8±3.13pg/ml) of group B. However, a significant 
increase (p<0.05) in group E was observed in the levels of CAT (31.74±1.43U/mg 
protein), SOD (52.85±1.23U/mg protein) and GSH (16.50±0.28U/ml) when compared to 
levels of CAT (11.04±0.44U/mg protein), SOD (33.36±1.27U/mg protein) and GSH 
(7.28±0.27U/mg protein) of group B. It may therefore be concluded that oral 
administration of Tetracarpidium conophorum at 400mg/kg can prevent the development 
of BPH induced by testosterone. 
 
 
 
 
 
